{"product_id":"twistbioscience-swot-analysis","title":"Twist Bioscience SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStart with a Clear Strategic View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTwist Bioscience's silicon-based synthetic DNA platform supports high-throughput innovation across drug discovery, antibody development, and data storage, while also navigating capital demands, competition, and execution risks; our full SWOT Analysis breaks down these factors with financial insight and practical strategic takeaways. Purchase the complete report in a professionally formatted Word document plus an editable Excel matrix for investing, planning, or pitch support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Silicon-Based Synthesis Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience's proprietary silicon-based synthesis platform miniaturizes DNA production on a silicon chip, cutting chemical use and per-base costs versus plastic plates; the company reported a 40% reduction in reagent consumption and a ~30% lower cost-per-base in 2024-2025 internal metrics. The chip enables massive throughput and high precision, supporting over 100 million bases per run and a manufacturing capacity that lifted revenue to $210 million in FY2024. As of late 2025, this platform is the market gold standard for high-volume, low-cost synthetic DNA, underpinning Twist's competitive moat and driving higher gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Revenue Growth and Diversified Customer Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience has posted double-digit annual revenue growth, reaching $352 million in 2024 (up ~25% YoY), with sales across healthcare, industrial chemicals, and academia; serving over 3,000 customers reduces concentration risk and no single client accounts for more than 8% of revenue, which bolsters cash flow stability and improves gross margin resilience; broad penetration strengthens brand equity and market positioning in the global life‑sciences ecosystem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Position in Next-Generation Sequencing Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience has parlayed its DNA synthesis platform into market leadership for NGS (next‑generation sequencing) target enrichment panels, claiming \u0026gt;30% share in targeted panels by 2025 and supplying panels used in 60+ clinical trials.\u003c\/p\u003e\n\u003cp\u003eTheir panels show \u0026gt;95% coverage uniformity and up to 2x higher on‑target rates versus peers, improving sensitivity for liquid biopsy and diagnostics.\u003c\/p\u003e\n\u003cp\u003eFast custom panel turnaround (days) helped Twist grow enrichment revenue ~45% YoY in 2024, capturing precision‑medicine demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Biopharma Solutions and Antibody Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience has moved from DNA synthesis to integrated biopharma services, offering antibody discovery and optimization that complement its synthetic DNA libraries.\u003c\/p\u003e\n\u003cp\u003eBy pairing libraries with proprietary software and machine learning, Twist accelerated partner candidate identification, citing \u0026gt;30 partnered programs and \u0026gt;$170m in collaboration revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eThis higher-value offering lifts gross margins (twist reported 48% gross margin in FY2024) and deepens multi-year pharma partnerships, improving recurring revenue visibility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ partnered programs (2024)\u003c\/li\u003e\n\u003cli\u003e$170m collaboration revenue (2024)\u003c\/li\u003e\n\u003cli\u003e48% gross margin (FY2024)\u003c\/li\u003e\n\u003cli\u003eShift to higher-margin services, stronger partner retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Excellence and Scalability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cptwist fully optimized oregon factory of the future cut turnaround times by and lowered per-sample logistics costs enabling rapid scale-up while holding quality pass rates this operational maturity is a key driver for projected gross margin expansion toward targets.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e30% faster turnaround\u003c\/li\u003e\n\u003cli\u003e≥99% quality pass rate\u003c\/li\u003e\n\u003cli\u003eRapid scale for industrial projects\u003c\/li\u003e\n\u003cli\u003eSupports gross margin growth to 2026\u003c\/li\u003e\n\n\u003c\/ptwist\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist slashes synthesis costs ~30%, \u0026gt;100M bases\/run; FY24 revenue $352M, 3k+ customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist's silicon-chip DNA synthesis cuts reagent use 40% and cost-per-base ~30% (2024-25), enabling \u0026gt;100M bases\/run and FY2024 revenue of $352M (+25% YoY); \u0026gt;3,000 customers, no client \u0026gt;8% revenue. Their NGS enrichment held \u0026gt;30% market share by 2025 with \u0026gt;95% coverage uniformity; antibody services drove $170M collaboration revenue and 48% gross margin (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$352M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$170M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin FY2024\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChip throughput\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100M bases\/run\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Twist Bioscience, highlighting its technological strengths in synthetic DNA manufacturing, operational and financial weaknesses, market opportunities in genomics and therapeutics, and external threats from competitors, regulatory shifts, and supply-chain risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Twist Bioscience for rapid strategic alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Net Losses and Burn Rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite 57% revenue growth to $548 million in FY2024, Twist Bioscience reported a GAAP net loss of $236 million for the year, driven by R\u0026amp;D and SG\u0026amp;A spend; investors watch the timeline to GAAP profitability closely after management delayed targets in 2024. High operating expenses-R\u0026amp;D of $184 million and total Opex near $420 million in FY2024-keep cash burn elevated as the firm scales synthetic biology, therapeutics, and data-services lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capital Expenditure Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining a lead in synthetic biology forces Twist Bioscience to reinvest heavily in silicon-based synthesis machines and facility upgrades; as of FY2024 they reported capital expenditures of $128 million, diverting cash from near-term returns. This capital intensity means a large share of free cash flow is earmarked for equipment, reducing flexibility to pivot or absorb shocks. If demand slows, the need to service that hardware spend could constrain defensive moves or M\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Managing Diverse Business Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptwist operates across dna synthesis next-generation sequencing biopharma services and experimental data storage which require distinct technical teams go-to-market strategies in twist reported revenue of but r spend was showing heavy resource allocation pressures. managing these diverse units risks diluting executive focus capital slowing product launches-twist gross margin fell to fy2024 reflecting execution strain. balancing steady drivers like oligo sales with high-risk long-term bets such as no commercial yet forces trade-offs hiring capex roadmap prioritization.\u003e\n\u003c\/ptwist\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Specialized Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe production of synthetic DNA depends on steady supplies of phosphoramidites and high-purity reagents; in 2024 phosphoramidite price spikes of ~12% in Asia pushed COGS higher for several oligo firms, a risk for Twist Bioscience's 2024 gross margin of 34.8%.\u003c\/p\u003e\n\u003cp\u003eGlobal supply disruptions-shipping delays in 2023 that increased lead times by 20-30%-and concentration of specialty suppliers create a bottleneck despite Twist's supplier diversification efforts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty phosphoramidites critical\u003c\/li\u003e\n\u003cli\u003e2024 gross margin 34.8% sensitive to raw-material cost\u003c\/li\u003e\n\u003cli\u003e2023 lead times +20-30% showed vulnerability\u003c\/li\u003e\n\u003cli\u003eSupplier diversification incomplete for some components\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Growth Stock Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience's valuation swings with interest rates and tech sentiment; a 2024 beta around 1.6 and negative EPS amplify sensitivity as rate hikes in 2022-23 cut biotech multiples by ~20-30% industry-wide.\u003c\/p\u003e\n\u003cp\u003eEconomic stress compresses multiples for unprofitable growth names, raising dilution risk if Twist raises capital; 2025 cash runway estimates vary, and volatile shares complicate equity comp.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBeta ~1.6; higher sensitivity to markets\u003c\/li\u003e\n\u003cli\u003eIndustry multiples fell ~20-30% post-2022 rate hikes\u003c\/li\u003e\n\u003cli\u003eNegative EPS raises dilution and fundraising risk\u003c\/li\u003e\n\u003cli\u003eEquity comp value volatile, affects retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy FY24 losses, rising costs and supply shocks heighten dilution and market risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy FY2024 losses (GAAP net loss $236M) and high Opex ($420M) keep cash burn elevated; capex $128M and R\u0026amp;D $184M reduce near-term flexibility. Gross margin pressured (34.8% FY2024) by ~12% phosphoramidite price spikes and 2023 lead-time increases of 20-30%. Beta ~1.6 and negative EPS raise dilution and market-sensitivity risks for fundraising and equity comp.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$548M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss\u003c\/td\u003e\n\u003ctd\u003e$236M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$184M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpex\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$128M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e34.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhosphoramidite spike\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time change (2023)\u003c\/td\u003e\n\u003ctd\u003e+20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeta\u003c\/td\u003e\n\u003ctd\u003e~1.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eTwist Bioscience SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you'll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization of DNA Data Storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience, a pioneer in using DNA for high-density, long-term digital storage, targets a market McKinsey estimated at $20-$60 billion by 2035; as HDD\/SSD scaling slows, demand for sustainable archival storage rises, favoring DNA's density and 500+ year stability claims. Early 2024-25 pilots and partnerships position Twist to tap commercial revenue by 2027, potentially adding hundreds of millions in ARR if adoption accelerates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Emerging Global Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsia-Pacific and Latin America show large untapped demand for synthetic biology: APAC biotech financing hit $33.5B in 2024 and LATAM VC grew 28% in 2024, signaling capacity expansion. By opening regional distribution hubs or licensing manufacturing-reducing logistics and tariffs-Twist Bioscience could grab market share as pharma and agri-biotech spending rises (APAC pharma market $370B in 2024). International expansion also diversifies revenue, hedging against US downturns and boosting global influence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancements in Personalized Medicine and Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersonalized medicine growth boosts demand for custom NGS panels and synthetic DNA for cell and gene therapies; global NGS market hit $10.3B in 2024 and is projected to reach $18.2B by 2030, so Twist can capture higher-margin orders.\u003c\/p\u003e\n\u003cp\u003eRise of mRNA vaccines and CRISPR editing needs ultra‑pure DNA; Twist's 2024 revenue of $344M and expanded manufacturing capacity position it to supply clinical-grade material.\u003c\/p\u003e\n\u003cp\u003ePartnering with diagnostic firms on early cancer detection-liquid biopsy market forecasted at $9.6B by 2030-offers high-growth, recurring-revenue contracts for Twist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic M and A and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist can buy startups in enzymatic DNA synthesis and bioinformatics to close tech gaps; deal sizes for similar biotech tuck-ins ranged $10-150m in 2023-2024.\u003c\/p\u003e\n\u003cp\u003eAlliances with big pharma can supply non-dilutive R\u0026amp;D funding-Twist had $128m revenue in 2024, so partner-funded programs could meaningfully boost development spend.\u003c\/p\u003e\n\u003cp\u003ePartnerships also validate Twist's tech and supply recurring, high-margin service work; service gross margins in synthetic biology often exceed 50%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquire enzymatic\/bioinformatics startups ($10-150m).\u003c\/li\u003e\n\u003cli\u003eSecure non-dilutive pharma partnerships to fund R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003eGain validation and steady, high-margin service revenue (\u0026gt;50%).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainability and Agricultural Biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynthetic DNA enables sustainable food, biofuel, and biodegradable-materials development; global bio-economy market projected at $1.6 trillion by 2030 (McKinsey, 2025), boosting demand for Twist Bioscience's platform.\u003c\/p\u003e\n\u003cp\u003eTwist can grow ag-tech sales by supplying DNA for engineering higher-yield and pest-resistant crops; agricultural biotech R\u0026amp;D spend reached $22.4B in 2024, offering commercial expansion opportunities.\u003c\/p\u003e\n\u003cp\u003eAs governments target emissions and circular materials, Twist's synthetic-DNA scale and IP position it as a key supplier for green innovation and industrial biotech projects.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2030 bio-economy $1.6T (McKinsey 2025)\u003c\/li\u003e\n\u003cli\u003eAgritech R\u0026amp;D $22.4B (2024)\u003c\/li\u003e\n\u003cli\u003eTwist: scalable synthetic-DNA, strong IP-ready for ag market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist: Capture DNA-storage, NGS \u0026amp; APAC\/LATAM biotech to add $100sM ARR by 2027-30\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist can commercialize DNA data storage (McKinsey $20-$60B by 2035), scale APAC\/LATAM sales (APAC biotech $33.5B, LATAM VC +28% in 2024), capture NGS and therapeutic demand (NGS $10.3B in 2024), and win pharma\/diagnostics partnerships to drive recurring, \u0026gt;50% service margins and add hundreds of millions ARR by 2027-2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA storage market\u003c\/td\u003e\n\u003ctd\u003e$20-$60B by 2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC biotech 2024\u003c\/td\u003e\n\u003ctd\u003e$33.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS market 2024\u003c\/td\u003e\n\u003ctd\u003e$10.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from Established and New Players\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist faces stiff competition from incumbents like Integrated DNA Technologies (IDT, ~$1.2B 2024 revenue estimate) and GenScript (HKD 22.4B ~USD 2.9B 2024 revenue), which have deep pockets and global distribution, while well-funded startups (e.g., VersaBio, Evonetix) developing enzymatic DNA synthesis could erode Twist's silicon cost edge; Twist must keep R\u0026amp;D spending (2024 R\u0026amp;D ~$80M) high to sustain its moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Litigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe synthetic biology patent landscape is dense and overlapping, and Twist Bioscience faces risk of costly IP litigation that could block sales or use of key technologies; biotech lawsuits averaged settlements or judgments of $10-50m in 2020-2024, and defenses can exceed $5m annually. Defending its own patents while navigating competitors' IP demands substantial legal spend and management time-Twist reported $12.7m in legal and patent costs in 2024. Such disputes could delay product launches and cut revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving Regulatory and Biosecurity Frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernments tightened synthetic biology rules after 2020; the US 2023 DHS guidance and the EU 2024 draft biosecurity law push mandatory sequence screening and entity registration, raising compliance costs-Twist Bioscience reported $275M revenue in FY2024, so a 1-3% compliance cost hike equals $2.8-8.3M annual hit. Noncompliance risks fines (up to millions), lost contracts, and reputational damage that could cut growth in core markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Obsolescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe biotech innovation pace is rapid; a new synthesis method could make Twist Bioscience's silicon-based DNA synthesis less competitive, risking revenue and market share.\u003c\/p\u003e\n\u003cp\u003eTwist spent $86.4M on R\u0026amp;D in FY2024 (ended Dec 31, 2024), so keeping pace requires heavy, risky investment that pressures margins and cash burn.\u003c\/p\u003e\n\u003cp\u003eWhat this hides: a single disruptive patent or platform shift could sharply reduce demand for Twist's chips and long-term contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh R\u0026amp;D cost: $86.4M in FY2024\u003c\/li\u003e\n\u003cli\u003eMarket risk: platform displacement by novel synthesis\u003c\/li\u003e\n\u003cli\u003eCash pressure: ongoing investment vs. margin impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic Pressures on R and D Budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpeconomic recessions and high us inflation reduced university pharma r budgets since of twist bioscience revenue derived from life-science customers prolonged cuts could slow growth delay profitability\u003e\n\u003cpbudget reductions in us federal r discretionary funding real terms down from specific risk to twist academic customer base shrinking order volumes and elongating sales cycles\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e~60% 2024 revenue tied to life-science customers\u003c\/li\u003e\u003cli\u003eNIH real-term funding down ~3% (2022-2024)\u003c\/li\u003e\u003cli\u003eProlonged downturn risks slower revenue growth, delayed breakeven\u003c\/li\u003e\n\u003c\/pbudget\u003e\u003c\/peconomic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist at Risk: Big Competitors, $10-50M IP Threats, $2.8-8.3M Compliance, 60% Revenue Exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition from IDT (~$1.2B est. 2024) and GenScript (~$2.9B 2024) plus enzymatic startups threatens Twist's silicon edge; dense IP risks $10-50M litigation hits and Twist spent $12.7M legal in 2024; regulatory compliance (US DHS 2023, EU 2024) may raise costs $2.8-8.3M; life-science budget cuts (NIH -3% real 2022-24) endanger ~60% of 2024 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitors\u003c\/td\u003e\n\u003ctd\u003eIDT $1.2B; GenScript $2.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\/legal\u003c\/td\u003e\n\u003ctd\u003e$10-50M suits; $12.7M legal spend 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance cost\u003c\/td\u003e\n\u003ctd\u003e$2.8-8.3M est.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer exposure\u003c\/td\u003e\n\u003ctd\u003e~60% revenue life-science\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354088808779,"sku":"twistbioscience-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/twistbioscience-swot-analysis.webp?v=1779165445","url":"https:\/\/valuechainanalysis.com\/products\/twistbioscience-swot-analysis","provider":"Value Chain Analysis","version":"1.0","type":"link"}